Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can magnetic pulses calm the brain in PTSD and depression?

NCT ID NCT07327385

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how two types of noninvasive brain stimulation affect brain activity and the body's stress system in people with both PTSD and major depression. Fifty adults will receive both active and sham stimulation in random order, with brain and heart measurements taken right before and after each session. The goal is to understand how these treatments work, not to provide long-term relief.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged 18 to 65 years. 2. Clinical diagnosis of posttraumatic stress disorder (PTSD) according to DSM-5 criteria, confirmed by a board-certified psychiatrist. 3. Presence of comorbid major depressive disorder with stable clinical condition. 4. PTSD symptom severity defined as: PTSD Checklist for DSM-5, Chinese version (C-PCL-5) total score ≥ 31. 5. Depressive symptom severity defined as: Patient Health Questionnaire-9 (PHQ-9) total score ≥ 10. 6. Stable psychiatric medication regimen for at least 4 weeks prior to enrollment, or medication-free. 7. Ability to understand the study procedures and provide written informed consent. 8. Normal or corrected-to-normal vision and hearing. 9. Ability to comply with study procedures and visit schedule. Exclusion Criteria: 1. Lifetime diagnosis of schizophrenia spectrum disorders, bipolar disorder, or pervasive developmental disorders. 2. Alcohol or substance use disorder (excluding caffeine and nicotine) within the past 6 months. 3. Ongoing trauma-focused psychotherapy during the study period. 4. Prior exposure to repetitive TMS treatment exceeding five sessions. 5. Current or recent (within the past year) suicidal ideation or behavior, defined as: PHQ-9 item 9 score ≥ 1, confirmed by clinical psychiatric evaluation. 6. Self-injurious behavior requiring medical attention within the past 3 months. 7. History of epilepsy, seizure disorder, or family history of epilepsy. 8. Significant neurological disorders, severe traumatic brain injury, or history of brain surgery. 9. Presence of implanted metallic or electronic medical devices (e.g., pacemakers, cochlear implants, neurostimulators). 10. Uncontrolled major medical illnesses or severe cardiovascular disease. 11. Pregnancy or breastfeeding. 12. Skin lesions or infections at the stimulation site. 13. Use of medications known to significantly lower seizure threshold (e.g., tricyclic antidepressants or certain analgesics). 14. Any condition deemed by the investigator to render the participant unsuitable for rTMS.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depression - major depressive disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tri-Service General Hospital

    Taipei, Neihu, 114, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.